OPDC Scientific Advisory Board

OPDCSAB
OPDC SAB Meeting March 2017

Patrik Brundin

Patrik Brundin

Director of the Center for Neurodegenerative Science, Jay Van Andel Endowed Chair in Parkinson Research

Professor Brundin leads the Center for Neurodegenerative Science at the Van Andel Research Institute and has a joint appointment at Lund University. His research team is focused on experimental models and novel therapies in PD.

John Davis

johndavis

Chief Scientific Officer of  the ARUK Oxford Drug Discovery Institute

John Davis has 20 years of drug discovery expertise from target to phase IIa and has helped steer a dozen drug candidates into clinical development and to four positive proof of concepts

Howard Federoff

Howard J Federoff

Vice chancellor for health affairs and system Chief Executive Officer, UC Irvine Health

Dr. Federoff’s research interests include gene therapy and neurodegenerative diseases such as Parkinson’s, Alzheimer’s, and prion diseases; he holds a number of medical patents with a number of other patents pending.

Thomas Gasser

Thomas_Gasser

Professor of Neurology and Director of the Department of Neurodegenerative Diseases at Hertie Institute for Clinical Brain Research, University of Tubingen

His research is primarily focused on the identification of genes and loci that are involved in the development of Parkinson’s disease, and the analysis of the functional consequences of variations in the identified genes.

Ellen Gelpi

Ellen Gelpi

Head of the Neurological Tissue Bank of the Biobank-Hospital Clinic-IDIBAPS

Dr Gelpi’s main research interest is focused on the neuropathological substrate of neurological disorders, in particular of neurodegenerative diseases.

Donald Grosset

Donald Grosset

Consultant Neurologist and Honorary Professor in Neurology at the University of Glasgow; Chief Investigator of PRoBAND (Tracking Parkinson's)

Professor Grosset’s research is focused on diagnostic accuracy and new treatments for Parkinson’s disease, as well as population studies including risks of family inheritance of the condition.

John Isaac

John Isaac

Senior Director, Neuroscience, J&J Innovations

Dr Isaac joined Johnson & Johnson in September 2016. In this role he uses his drug discovery and scientific experience to identify and advance external opportunities in the areas of Alzheimer’s Disease and Mood Disorders. He was previously the Head of Neuroscience and Mental Health at The Wellcome Trust. Prior to that he led a team of labs dedicated to identifying new therapies for Alzheimer's disease and schizophrenia at Eli Lilly and Company.

Birgitt Liss

Birgitt Liss

Head of Institute of Applied Physiology, Ulm University

Professor Liss is interested in age-dependent function and gene expression of individual neurons in view of their selective vulnerability to disease.

Paola Piccini

Paola_Piccini

Head of the Centre of Neuroinflammation and Neurodegeneration, and Professor of Neurology, Imperial College London

Professor Piccini’s main research has focussed on movement disorders and predominantly on the use of Positron emission tomography (PET) as a method of investigating aetiology, effects and complications of therapies.

Paul Reading

PaulReading

President British Sleep Society, Consultant Neurologist, James Cook University Hospital

Dr Reading’s particular interests are narcolepsy, abnormal sleep in neurodegenerative disease (particularly parkinsonian syndromes) and parasomnias. He has been running a bi-weekly Neurology Sleep Clinic for over 10 years

Clive Svendsen

Clive Svendsen

Director, Cedars-Sinai Regenerative Medicine Institute

Professor Svendsen's research concerns modeling and treating neurodegenerative disorders such as amyotrophic lateral sclerosis (ALS or Lou Gehrig's disease) and Parkinson's disease using a combination of stem cells and powerful growth factors.

Kevin Talbot

Kevin Talbot

Professor of Motor Neuron Biology, Nuffield Department of Clinical Neurosciences,University of Oxford

Professor Kevin Talbot is a Consultant Neurologist and Professor of Motor Neuron Biology at the Oxford University Nuffield Department of Clinical Neurosciences.

His research interests are in understanding the molecular basis of motor neuron and other neurodegenerative disorders.